Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PASylated anti-VEGFR2 Adnectin
- Development stage
- Preclinical
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
PASylated anti-VEGFR2 Adnectin is a preclinical-stage recombinant fusion protein designed to inhibit angiogenesis. It consists of an anti-VEGFR2 Adnectin (specifically Adnectin C, a monobody derived from the tenth type III domain of human fibronectin) genetically fused to a biodegradable Pro/Ala/Ser (PAS) polypeptide sequence (specifically a 200-amino-acid PAS sequence). This PASylation technology, developed by XL-protein, significantly increases the hydrodynamic volume of the small Adnectin scaffold, thereby extending its plasma half-life and improving its pharmacokinetic profile without compromising its binding affinity to VEGFR2. By binding to VEGFR2, the fusion protein blocks VEGF-mediated signaling pathways, potentially inhibiting tumor angiogenesis and metastasis.
- Other names
- Adnectin C-PASAdnectin C-PAS#1(200)PAS-VEGFR2 AdnectinPAS-VEGFR-2 AdnectinPAS-VEGFR 2 AdnectinPASylated Adnectin C
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on PASylated anti-VEGFR2 Adnectin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PASylated anti-VEGFR2 Adnectin.